YuanDa Pharmaceutical: Innovative drug in research receives FDA Fast Track designation.

On August 9, Yuanda Pharmaceutical announced that the innovative nuclear drug GPN01530-2 targeting FAP has received Fast Track designation from the FDA. GPN01530-2 has currently been approved by the FDA to conduct Phase I/II clinical studies for the diagnosis of solid tumors. This Fast Track designation is expected to expedite the future development and commercialization process of GPN01530-2.